Amicus Therapeutics (FOLD) to Release Earnings on Thursday

Amicus Therapeutics (NASDAQ:FOLD) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Amicus Therapeutics to post earnings of $0.08 per share and revenue of $136.32 million for the quarter.

Amicus Therapeutics Stock Up 2.6 %

Shares of Amicus Therapeutics stock opened at $7.09 on Thursday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics has a 1-year low of $6.20 and a 1-year high of $12.65. The business’s fifty day moving average price is $8.26 and its two-hundred day moving average price is $9.44. The company has a market capitalization of $2.18 billion, a P/E ratio of -39.37, a PEG ratio of 1.51 and a beta of 0.79.

Analysts Set New Price Targets

Several research firms recently weighed in on FOLD. Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.